With 4.56 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.77 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $4.85 whereas the lowest price it dropped to was $3.67. The 52-week range on NRXP shows that it touched its highest point at $7.33 and its lowest point at $1.10 during that stretch. It currently has a 1-year price target of $31.67. Beta for the stock currently stands at 1.10.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of NRXP was up-trending over the past week, with a rise of 204.58%, but this was up by 291.60% over a month. Three-month performance surged to 210.67% while six-month performance rose 116.74%. The stock gained 11.94% in the past year, while it has gained 111.82% so far this year. A look at the trailing 12-month EPS for NRXP yields -2.15 with Next year EPS estimates of 0.32. For the next quarter, that number is -0.32. This implies an EPS growth rate of 53.58% for this year and 117.24% for next year.
Float and Shares Shorts:
At present, 11.37 million NRXP shares are outstanding with a float of 9.20 million shares on hand for trading. On 2024-10-31, short shares totaled 0.68 million, which was 635.0 higher than short shares on 1727654400. In addition to Dr. Jonathan C. Javitt M.D., M.P.H. as the firm’s Co-Founder, Chief Scientist Officer, Chairman & Interim CEO, Mr. Richard Clavano Narido serves as its CFO & Treasurer.
Institutional Ownership:
Through their ownership of 0.060500003 of NRXP’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-06-30, NRXP reported revenue of $0.0 and operating income of -$3022000.0. The EBITDA in the recently reported quarter was -$1659000.0 and diluted EPS was -$0.15.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for NRXP since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With NRXP analysts setting a high price target of 45.0 and a low target of 19.0, the average target price over the next 12 months is 31.66667. Based on these targets, NRXP could surge 865.67% to reach the target high and rise by 307.73% to reach the target low. Reaching the average price target will result in a growth of 579.54% from current levels.
Analysts have provided yearly estimates in a range of -$0.78951 being high and -$3.22257 being low. For NRXP, this leads to a yearly average estimate of -$1.85667.
